Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -163.38% is 81% above its 4-year average of -865.15%, near the high end of its 4-year range (-166806.30%–-74.62%).
18.71% above its 12-month average of -201.00%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -216.69%.
EBITDA MARGIN
-163.38%
EBITDA MARGIN AVG TTM
-201.00%
EBITDA MARGIN AVG 3Y
-145.18%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.71%
CURRENT VS 3Y AVG
-12.54%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
bioAffinity Technologies, Inc.
Market Cap
$2.59M
EBITDA Margin
-163.38%
TTM Avg
-201.00%
3Y Avg
-145.18%
5Y Avg
N/A
Market Cap
$2.47M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.37M
EBITDA Margin
-100324.78%
TTM Avg
-75768.79%
3Y Avg
-56097.78%
5Y Avg
-38080.91%
Market Cap
$3.09M
EBITDA Margin
-4291.67%
TTM Avg
-3563.06%
3Y Avg
-8274.29%
5Y Avg
-15578.54%
Market Cap
$3.13M
EBITDA Margin
-22711.52%
TTM Avg
-15924.10%
3Y Avg
-12940.13%
5Y Avg
-12940.13%
Market Cap
$3.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.44M
EBITDA Margin
-2030.10%
TTM Avg
-2765.29%
3Y Avg
-1907.45%
5Y Avg
-2238.98%
Market Cap
$3.48M
EBITDA Margin
-334.54%
TTM Avg
-323.48%
3Y Avg
-700.81%
5Y Avg
-1335.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $2.59M | -163.38% | -201.00% | -145.18% | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.47M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.37M | -100324.78% | -75768.79% | -56097.78% | -38080.91% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.09M | -4291.67% | -3563.06% | -8274.29% | -15578.54% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | -22711.52% | -15924.10% | -12940.13% | -12940.13% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.92M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.37M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.44M | -2030.10% | -2765.29% | -1907.45% | -2238.98% |
| Evogene Ltd. (EVGN)vs › | $3.48M | -334.54% | -323.48% | -700.81% | -1335.84% |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
Gross Margin
23.2%
EBITDA Margin
-163.4%
Operating Margin
-171.6%
Net Margin
-257.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -216.69% |
| 2026-03-31 | -259.15% |
| 2025-12-31 | -189.18% |
| 2025-09-30 | -150.72% |
| 2025-06-30 | -189.24% |
| 2025-03-31 | -133.39% |
| 2024-12-31 | -126.51% |
| 2024-09-30 | -77.54% |
| 2024-06-30 | -80.78% |
| 2024-03-31 | -74.62% |
| 2023-12-31 | -99.11% |
| 2023-09-30 | -749.43% |
| 2023-06-30 | -8900.59% |
| 2023-03-31 | -166806.30% |
| 2022-12-31 | -68900.72% |
| 2022-09-30 | -84815.91% |
| 2022-06-30 | -52303.14% |
